Hongbo Wang

List of Publications by Year
in descending order

38 papers	1,232 citations	361413 20 h-index	414414 32 g-index
40 all docs	40 docs citations	40 times ranked	1872 citing authors

#	Article	IF	Citations
1	TRPC channels: Structure, function, regulation and recent advances in small molecular probes. , 2020, 209, 107497.		126
2	A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis. Molecular Cancer Therapeutics, 2011, 10, 69-79.	4.1	118
3	H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicology and Applied Pharmacology, 2018, 341, 98-105.	2.8	82
4	Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharmaceutica Sinica B, 2017, 7, 52-58.	12.0	62
5	A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth. International Journal of Nanomedicine, 2018, Volume 13, 4549-4561.	6.7	59
6	Activating Transcription Factor 3 Activates p53 by Preventing E6-associated Protein from Binding to E6. Journal of Biological Chemistry, 2010, 285, 13201-13210.	3.4	46
7	Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer. Cancer Letters, 2018, 432, 47-55.	7.2	45
8	Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels. Journal of Medicinal Chemistry, 2017, 60, 4680-4692.	6.4	44
9	Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Letters, 2008, 268, 89-97.	7.2	43
10	MDM2 Mediates Ubiquitination and Degradation of Activating Transcription Factor 3. Journal of Biological Chemistry, 2010, 285, 26908-26915.	3.4	43
11	A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells. Neoplasia, 2011, 13, 611-IN6.	5.3	41
12	A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility. Journal of Natural Products, 2018, 81, 524-533.	3.0	39
13	PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression inÂvitro and inÂvivo. Acta Pharmaceutica Sinica B, 2020, 10, 289-300.	12.0	39
14	The Stress Response Mediator ATF3 Represses Androgen Signaling by Binding the Androgen Receptor. Molecular and Cellular Biology, 2012, 32, 3190-3202.	2.3	38
15	Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors. Molecules, 2018, 23, 24.	3.8	38
16	Nicotinic ACh receptor Î±7 inhibits PDGFâ€induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3. British Journal of Pharmacology, 2019, 176, 4388-4401.	5.4	38
17	Design, synthesis, nitric oxide release and antibacterial evaluation of novel nitrated ocotillol-type derivatives. European Journal of Medicinal Chemistry, 2015, 101, 71-80.	5.5	36
18	Design, synthesis, and discovery of ocotillol-type amide derivatives as orally available modulators of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 161, 118-130.	5.5	27

#	Article	IF	Citations
19	LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain. Frontiers in Pharmacology, 2019, 10, 53.	3.5	23
20	Discovery, synthesis of novel fusidic acid derivatives possessed amino-terminal groups at the 3-hydroxyl position with anticancer activity. European Journal of Medicinal Chemistry, 2019, 162, 122-131.	5.5	23
21	Synthesis, Characterization, and Anticancer Activities Evaluation of Compounds Derived from 3,4-Dihydropyrimidin-2(1H)-one. Molecules, 2019, 24, 891.	3.8	22
22	Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo. Toxicology Letters, 2020, 331, 112-121.	0.8	21
23	Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 10286-10296.	6.4	19
24	PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Scientific Reports, 2019, 9, 5692.	3.3	17
25	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles. European Journal of Medicinal Chemistry, 2022, 232, 114207.	5.5	16
26	Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo. Frontiers in Pharmacology, 2019, 10, 903.	3.5	14
27	Design, Synthesis, and Biological Evaluation of Novel Nitrogen Heterocycle-Containing Ursolic Acid Analogs as Antitumor Agents. Molecules, 2019, 24, 877.	3.8	14
28	NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis. ELife, 2021, 10, .	6.0	13
29	PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer. Toxicology and Applied Pharmacology, 2020, 398, 115019.	2.8	12
30	Discovery and synthesis of 3- and 21-substituted fusidic acid derivatives as reversal agents of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2019, 182, 111668.	5.5	11
31	Pyxinol bearing amino acid residues: Easily achievable and promising modulators of P-glycoprotein-mediated multidrug resistance. European Journal of Medicinal Chemistry, 2021, 216, 113317.	5.5	11
32	Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation. Cancer Chemotherapy and Pharmacology, 2020, 85, 195-204.	2.3	10
33	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity. European Journal of Medicinal Chemistry, 2021, 211, 113107.	5.5	10
34	Novel Fluorescent Pyxinol-Based Probes: Design, Synthesis and Biological Evaluation. Chinese Journal of Organic Chemistry, 2017, 37, 2109.	1.3	10
35	Benzothiazole Amides as TRPC3/6 Inhibitors for Gastric Cancer Treatment. ACS Omega, 2021, 6, 9196-9203.	3.5	8
36	Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome. PLoS ONE, 2014, 9, e114688.	2.5	6

#	Article	IF	Citations
37	PCC0208018 exerts antitumor effects by activating effector T cells. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841984336.	2.1	4
38	PCC-0105002, a novel small molecule inhibitor of PSD95-nNOS protein-protein interactions, attenuates neuropathic pain and corrects motor disorder associated with neuropathic pain model. Toxicology and Applied Pharmacology, 2021, 429, 115698.	2.8	4